3 results
The study will assess the safety of a sex hormone (levonorgestrel) releasing T-shaped intrauterine contraceptive system in female adolescents under 18 years of age. The incidence of adverse events over 12 month treatment period will be the main…
Primary Objectives* Phase 1b lead-in: To assess safety and tolerability of a single dose level of avelumab in combination withincreasing dose levels of other immune modulators in combination with a single doselevel of avelumab in patients with…
This study is an open-label, non-randomized extension to study CCDZ173X2201. It aims to provide treatment with CDZ173 to patients withAPDS/PASLI who participated in study CCDZ173X2201 or who were treated previously with PI3Kδ inhibitors other than…